This ensures safe and effective dose adjustments
Dietary optimization remains foundational regardless of medication use
7.2 mg Wegovy and Comorbidities: Diabetes, Cardiovascular Outcomes, Metabolic Health An evidence-based overview of how higher-dose Wegovy 7.2 mg (semaglutide) may influence type 2 diabetes control, cardiovascular outcomes, kidney function and overall metabolic health, based on current clinical trial and real-world data
And there's no home test to measure that loss
Since semaglutide is highly effective at promoting weight loss, patients may be at increased risk through this indirect pathway
Glucagon signaling affects how the liver processes fats, potentially explaining why some trials showed enhanced lipid improvements compared to GLP-1 only medications